Georgina V. Long, MD, FRACP, PhD, of The University of Sydney’s Melanoma Institute, presents updated progression-free survival (PFS) data in the RELATIVITY-047 trial combining dual checkpoint inhibitors relatlimab and nivolumab in treatment-naive patients with advanced melanoma. The RELA and NIVO combo demonstrated a 22% reduction in progression versus NIVO alone. Dr. Long also reports the first disclosure of the key secondary endpoints of overall survival (OS) and overall response rate (ORR) from the trial.
Dr. Long reported honoraria from Bristol-Myers Squibb and Pierre Fabre. She also has consulting or advisory roles with the following companies: Aduro Biotech; Amgen; Array BioPharma; Boehringer Ingelheim; Bristol-Myers Squibb; Evaxion Biotech; Hexal; Highlight Therapeutics; Merck Sharpe & Dohme; Novartis; OncoSec; Pierre Fabre; QBiotics; Regeneron; Skyline Diagnostics; and Specialised Therapeutics.
